Deutsche Bank
CRSP icon

Deutsche Bank’s CRISPR Therapeutics CRSP Stock Holding History

Deutsche Bank’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.97M Buy
83,356
+12,864
+18% +$678K ﹤0.01% 1422
2025
Q4 		$3.7M Buy
70,492
+5,690
+9% +$341K ﹤0.01% 1463
2025
Q3 		$4.2M Buy
64,802
+7,542
+13% +$433K ﹤0.01% 1386
2025
Q2 		$2.79M Buy
57,260
+49,013
+594% +$1.9M ﹤0.01% 1519
2025
Q1 		$281K Buy
8,247
+114
+1% +$4.83K ﹤0.01% 2791
2024
Q4 		$320K Buy
8,133
+3,205
+65% +$151K ﹤0.01% 2878
2024
Q3 		$232K Buy
4,928
+114
+2% +$5.78K ﹤0.01% 2852
2024
Q2 		$260K Sell
4,814
-379
-7% -$21.9K ﹤0.01% 2665
2024
Q1 		$354K Buy
5,193
+136
+3% +$9.74K ﹤0.01% 2514
2023
Q4 		$317K Buy
5,057
+423
+9% +$23.4K ﹤0.01% 2621
2023
Q3 		$210K Buy
4,634
+2
+0% +$103 ﹤0.01% 2744
2023
Q2 		$260K Sell
4,632
-3,759
-45% -$213K ﹤0.01% 2735
2023
Q1 		$380K Buy
8,391
+3,724
+80% +$181K ﹤0.01% 2650
2022
Q4 		$190K Buy
4,667
+3,924
+528% +$208K ﹤0.01% 3005
2022
Q3 		$49K Sell
743
-123,149
-99% -$8.92M ﹤0.01% 3595
2022
Q2 		$7.53M Sell
123,892
-198
-0.2% -$11.6K ﹤0.01% 1114
2022
Q1 		$7.79M Buy
124,090
+121,485
+4,664% +$7.63M ﹤0.01% 1201
2021
Q4 		$197K Sell
2,605
-349
-12% -$30.5K ﹤0.01% 3395
2021
Q3 		$331K Sell
2,954
-1,263
-30% -$159K ﹤0.01% 3291
2021
Q2 		$683K Sell
4,217
-74,365
-95% -$9.04M ﹤0.01% 3023
2021
Q1 		$9.57M Sell
78,582
-82,684
-51% -$12.5M 0.01% 1216
2020
Q4 		$24.7M Buy
161,266
+107,681
+201% +$12.7M 0.02% 728
2020
Q3 		$4.48M Sell
53,585
-5,518
-9% -$489K ﹤0.01% 1310
2020
Q2 		$4.34M Buy
59,103
+56,046
+1,833% +$3.28M ﹤0.01% 1378
2020
Q1 		$130K Sell
3,057
-131,083
-98% -$6.77M ﹤0.01% 3142
2019
Q4 		$8.17M Buy
134,140
+97,244
+264% +$5.31M 0.01% 1191
2019
Q3 		$1.51M Buy
36,896
+36,420
+7,651% +$1.74M ﹤0.01% 2073
2019
Q2 		$21K Buy
476
+9
+2% +$360 ﹤0.01% 4792
2019
Q1 		$16K Sell
467
-4,818
-91% -$167K ﹤0.01% 4827
2018
Q4 		$150K Sell
5,285
-1,547
-23% -$53.8K ﹤0.01% 4029
2018
Q3 		$303K Sell
6,832
-155,561
-96% -$8.15M ﹤0.01% 4041
2018
Q2 		$9.54M Buy
162,393
+137,958
+565% +$7.86M ﹤0.01% 1793
2018
Q1 		$1.11M Sell
24,435
-33,830
-58% -$1.4M ﹤0.01% 3240
2017
Q4 		$1.37M Buy
58,265
+29,881
+105% +$568K ﹤0.01% 2993
2017
Q3 		$506K Buy
28,384
+27,884
+5,577% +$506K ﹤0.01% 3418
2017
Q2 		$8K Sell
500
-6,400
-93% -$106K ﹤0.01% 4688
2017
Q1 		$150K Buy
+6,900
New +$135K ﹤0.01% 3737

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deutsche Bank's CRSP Position: Q1 2026 in Review

Deutsche Bank increased its CRISPR Therapeutics (CRSP) stake by 18% in Q1 2026, buying an estimated $678K and bringing the position to 83,356 shares worth $3.97M. The position accounts for ﹤0.01% of the portfolio, ranked #1422.

Deutsche Bank first reported a position in CRSP in Q1 2017 and has held it in 37 quarters since. The position peaked at $24.7M in Q4 2020. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Deutsche Bank held 83,356 shares of CRISPR Therapeutics worth $3.97M as of Q1 2026.
  • Deutsche Bank bought 12,864 CRISPR Therapeutics shares in Q1 2026, an estimated $678K.
  • CRISPR Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #1422 holding.
  • Deutsche Bank first reported a position in CRISPR Therapeutics in Q1 2017 and has held it in 37 quarters since.
  • Deutsche Bank's CRISPR Therapeutics position peaked at $24.7M in Q4 2020.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.